FUNCTIONAL AREAS – Page 22

Submission delayed due to data gaps during global submissions – CAPA and strategy reset

Recognizing the symptoms of submission delays due to data gaps at an early stage is critical for timely corrective actions. Symptoms may manifest at various points, including during data collection,…

Uncontrolled parameter limits during system upgrades – how to rebuild the evidence package for inspectors

Detecting uncontrolled parameter limits requires acute awareness of various signals that may arise during operations. Symptoms can arise directly from system data or indirectly through observations by manufacturing or quality…

Submission delayed due to data gaps during agency query response – CAPA and strategy reset

Identifying the symptoms or signals associated with submission delays is crucial in initiating an effective investigation. Key indicators may include:Click to read the full article.

Uncontrolled parameter limits during system upgrades – how to prevent repeat validation failures

Identifying symptoms or signals that indicate a deviation due to uncontrolled parameter limits is the first step in the investigation process. Common indicators include:Click to read the full article.

Regulatory intelligence not applied during variation planning – FDA/EMA expectations and how to respond

Identifying symptoms or signals of inadequate regulatory intelligence application requires vigilance and a structured approach. Here are several common indicators:Click to read the full article.

Protocol deviation not investigated during inspection readiness – how to rebuild the evidence package for inspectors

Recognizing the early signals of uninvestigated protocol deviations is crucial for timely intervention. These symptoms may manifest in various ways, including:Click to read the full article.

Post-approval change misclassified during lifecycle management – approval risk analysis and mitigation

Risks of Misclassifying Post-Approval Changes During Lifecycle Management: An Investigative Approach In the pharmaceutical industry, the accurate classification of post-approval changes is critical to maintaining compliance with regulatory standards and…

Lubrication program failure after equipment breakdown – CAPA that links maintenance to product quality risk

Identifying symptoms or signals related to lubrication program failures is the first step in addressing concerns stemming from equipment breakdowns. Symptoms may manifest in various forms, prominently affecting equipment performance…

Inconsistent global strategy during variation planning – FDA/EMA expectations and how to respond

The first step in addressing inconsistencies is identifying the signals that indicate a potential deviation in the variation planning process. Common symptoms observed may include:Click to read the full article.

Utilities excursion event during inspection walkthrough – root cause approach for recurring failures

Identifying symptoms or signals of a utilities excursion event is crucial for prompt action. Common symptoms can be observed directly in the laboratory or manufacturing areas:Click to read the full…

Post-approval change misclassified during inspection preparation – FDA/EMA expectations and how to respond

Identifying the symptoms of PAC misclassification is critical to initiating a robust investigation process. Symptoms may manifest in various areas, including documentation, communication, and production activities. Here are some common…

Preventive maintenance overdue during inspection walkthrough – GMP documentation expectations for engineering teams

Recognizing early indicators of overdue preventive maintenance is crucial for sustained compliance and operational efficiency. Symptoms can present themselves in various forms:Click to read the full article.